In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...

The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

Delaware's highest court ruled on Thursday that nearly 75,000 patients suing four large drugmakers cannot introduce reports ...

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims that Zantac is linked to cancer.

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain.

Photo: Drew Angerer/Getty Images GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies were not reliable.

Zantac’s Developer Settles Lawsuits Claiming Cancer Link GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK’s shares rose by as much as 6.5% on Thursday before settling back slightly lower after it agreed a $2.2 billion settlement over lawsuits in the US, which alleged the drugmaker’s now ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.